Compare
Twist Bioscience Corp vs Immunocore Holdings plc vs ADMA Biologics, Inc. vs Adaptive Biotechnologies Corp
| Latest fiscal year | Twist Bioscience Corp TWST | Immunocore Holdings plc IMCR | ADMA Biologics, Inc. ADMA | Adaptive Biotechnologies Corp ADPT |
|---|---|---|---|---|
| Year ended | 2025-09-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $376.57M | $400.02M | $510.17M | $276.98M |
| Revenue growth (YoY) | +20.3% | +29.0% | +19.6% | +54.8% |
| Gross margin | 50.7% (computed) | n/a | 57.4% | 74.2% (computed) |
| Operating margin | -36.2% | -11.3% | 37.5% | -20.6% |
| Net margin | -20.6% | -8.9% | 28.8% | -21.5% |
| Net income | -$77.67M | -$35.51M | $146.93M | -$59.50M |
| EPS (Diluted) | -$1.30 | -$0.71 | $0.60 | -$0.39 |
| Operating cash flow | -$47.63M | -$10.71M | $50.40M | -$45.99M |
| Free cash flow | -$75.63M | -$15.05M | $27.82M | -$48.95M |
| Cash & equivalents | $183.05M | $467.71M | $87.63M | $70.50M |
| Total assets | $641.86M | $1.07B | $624.24M | $512.74M |
| Total liabilities | $168.90M | $686.24M | $146.92M | $287.74M |
| Shareholders' equity | $472.96M | $381.03M | $477.32M | $218.79M |
| Return on year-end equity | -16.4% | -9.3% | 30.8% | -27.2% |
| Shares outstanding | 60.63M | 50.69M | 237.87M | 153.78M |
Revenue, most recent five fiscal years
| Fiscal year | Twist Bioscience Corp | Immunocore Holdings plc | ADMA Biologics, Inc. | Adaptive Biotechnologies Corp |
|---|---|---|---|---|
| Latest | $376.57M Ended 2025-09-30 | $400.02M Ended 2025-12-31 | $510.17M Ended 2025-12-31 | $276.98M Ended 2025-12-31 |
| 1 year earlier | $312.97M Ended 2024-09-30 | $310.20M Ended 2024-12-31 | $426.45M Ended 2024-12-31 | $178.96M Ended 2024-12-31 |
| 2 years earlier | $245.11M Ended 2023-09-30 | $249.43M Ended 2023-12-31 | $258.21M Ended 2023-12-31 | $170.28M Ended 2023-12-31 |
| 3 years earlier | $203.56M Ended 2022-09-30 | $174.36M Ended 2022-12-31 | $154.08M Ended 2022-12-31 | $185.31M Ended 2022-12-31 |
| 4 years earlier | $132.33M Ended 2021-09-30 | $36.48M Ended 2021-12-31 | $80.94M Ended 2021-12-31 | $154.34M Ended 2021-12-31 |